In breast cancer, [89Zr]DFO-trastuzumab is paving the way towards the selection of the human epidermal growth factor receptor 2 (HER2)-positive patients for therapeutic antibodies that target this receptor. This evidence concerns the gene ERBB2 and breast cancer.